Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Relapsed T-acute lymphoblastic leukemia (T-ALL) presents significant therapeutic challenges due to limited treatment options.
• BH3 mimetics offer a targeted approach, but resistance mechanisms can limit their efficacy.

Purpose of the Study:

• To investigate resistance mechanisms to BH3 mimetics in T-ALL.
• To evaluate the preclinical efficacy of NWP-0476, a novel BCL-2/BCL-xL inhibitor, in T-ALL.
• To develop rational combination strategies for T-ALL treatment.

Main Methods:

• Utilized BH3 profiling to predict BH3 mimetic response in T-ALL.
• Employed isogenic control, venetoclax-resistant (ven-R), and NWP-0476-resistant (NWP-R) cells.
• Performed phosphokinase arrays to identify differentially regulated signaling pathways.

Main Results:

• Identified differential dependence on BCL-2 and BCL-xL in T-ALL subtypes.
• Discovered increased LCK and ACK1 signaling in resistant T-ALL cells.
• Demonstrated that LCK and ACK1 pathways drive resistance to BH3 mimetics.
• Showed synergistic efficacy of NWP-0476 and dasatinib in a T-ALL xenograft model without significant toxicity.

Conclusions:

• LCK and ACK1 signaling pathways are key regulators of BH3 mimetic resistance in T-ALL.
• Combination therapy of BH3 mimetics with tyrosine kinase inhibitors represents a promising strategy for relapsed T-ALL.